Nanotechnology for targeted modulation of mitophagy: molecular mechanisms, therapeutic applications, and translational perspectives.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanisms, nanotechnology design, and preclinical strategies without new human clinical data.
PubMed 42609046 · doi:10.1088/1748-605X/ae95c8
What was done
The authors conducted a narrative review summarizing the molecular mechanisms of mitophagy, engineering strategies for targeted nanoplatforms (such as mitochondria-targeting, stimuli-responsive activation, and ligand-mediated delivery), and translational considerations across various disease classes.
What was found
The abstract reports no numerical findings or quantitative outcomes. It provides a qualitative overview of mitophagy dysregulation in neurodegenerative, oncological, cardiovascular, metabolic, inflammatory, and musculoskeletal diseases, and outlines translational challenges concerning evaluation methodologies, biosafety, pharmacokinetics, and regulatory approval.
Why it matters
It integrates mechanistic pathways of mitophagy with nano-delivery engineering strategies to outline design principles for targeted mitochondrial therapeutics.
Limits
The review is narrative rather than systematic, with no stated search methodology or study quality assessment. No human clinical trial results are presented, and the discussed technologies remain largely in early preclinical development.
Cited by
- supports Mitophagy is the cellular process of selectively degrading and recycling poorly functioning mitochondria.